Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,281 to 1,300 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Comfort Talk® Training OSU vs Control OSU: No-shows in Q2FY16 (OSU) | 214 of 4,121 213 of 3,070 | -1.7 points -2.9 to -0.6 | 7,191 | NCT02427737 Comfort Talk and Economic Outcomes in MRI |
| C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic PCR Confirmed CDI Cases: Per-Protocol Population | 23 of 4,786 13 of 2,378 | -0.1 points -0.5 to 0.3 | 7,164 | NCT01887912 Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection |
| Rivaroxaban 15 mg OD vs Acetylsalicylic Acid 100 mg OD: deaths from any cause | 73 of 3,562 58 of 3,559 | 0.4 points -0.2 to 1.1 | 7,121 | NCT02313909 Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) |
| Rivaroxaban 15 mg OD vs Acetylsalicylic Acid 100 mg OD: serious adverse events | 466 of 3,562 434 of 3,559 | 0.9 points -0.7 to 2.4 | 7,121 | NCT02313909 Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With BARC Type 2, 3, or 5 | 141 of 3,555 250 of 3,564 | -3.0 points -4.1 to -2.0 | 7,119 | NCT02270242 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: serious adverse events | 262 of 3,555 370 of 3,564 | -3.0 points -4.3 to -1.7 | 7,119 | NCT02270242 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention |
| Intervention Arm Stage 1 vs Intervention Arm Stage II: serious adverse events | 89 of 1,671 50 of 5,447 | 4.4 points 3.4 to 5.6 | 7,118 | NCT01864603 Sustainable East Africa Research in Community Health |
| aTIV (Pooled) vs Licensed TIV: serious adverse events | 264 of 3,545 243 of 3,537 | 0.6 points -0.6 to 1.8 | 7,082 | NCT01162122 Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects |
| Comfort Talk® Training OSU vs Control OSU: No-shows in Q3FY16 (OSU) | 220 of 4,148 215 of 2,931 | -2.0 points -3.2 to -0.9 | 7,079 | NCT02427737 Comfort Talk and Economic Outcomes in MRI |
| V710 60 µg vs Placebo: Number of Participants With Invasive Staphylococcus Aureus Infection | 27 of 3,528 31 of 3,517 | -0.1 points -0.6 to 0.3 | 7,045 | NCT00518687 Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2) |
| V710 60 µg vs Placebo: Number of Participants With Staphylococcus Aureus Bacteremia and/or Deep Sternal Wound Infection | 22 of 3,528 27 of 3,517 | -0.1 points -0.6 to 0.3 | 7,045 | NCT00518687 Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2) |
| V710 60 µg vs Placebo: Number of Participants With Surgical-site Staphylococcus Aureus Infection | 53 of 3,528 75 of 3,517 | -0.6 points -1.3 to -0.0 | 7,045 | NCT00518687 Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2) |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With Ischemic Episode | 135 of 3,524 137 of 3,515 | -0.1 points -1.0 to 0.8 | 7,039 | NCT02270242 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention |
| Placebo + Ticagrelor vs Aspirin + Ticagrelor: deaths from any cause | 34 of 3,524 45 of 3,515 | -0.3 points -0.8 to 0.2 | 7,039 | NCT02270242 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention |
| Nesiritide vs Placebo: Number of Patients With Renal Impairment | 1,032 of 3,498 968 of 3,509 | 1.9 points -0.2 to 4.0 | 7,007 | NCT00475852 A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 30 | 126 of 3,498 141 of 3,509 | -0.4 points -1.3 to 0.5 | 7,007 | NCT00475852 A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 180 | 429 of 3,498 447 of 3,509 | -0.5 points -2.0 to 1.1 | 7,007 | NCT00475852 A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure |
| Nesiritide vs Placebo: serious adverse events | 5 of 3,498 2 of 3,509 | 0.1 points -0.1 to 0.3 | 7,007 | NCT00475852 A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure |
| aTIV (Pooled) vs Licensed TIV: Number of Subjects Reporting Healthcare Utilization Across Vaccine Groups | 275 of 3,499 289 of 3,502 | -0.4 points -1.7 to 0.9 | 7,001 | NCT01162122 Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects |
| N2O Group (FiO2 0.3) vs N2O Free Group (FiO2 0.3): Pulmonary Embolism | 18 of 3,483 22 of 3,509 | -0.1 points -0.5 to 0.3 | 6,992 | NCT00430989 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=65
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02427737-68734ccf",
"title": "Comfort Talk® Training OSU vs Control OSU: No-shows in Q2FY16 (OSU)",
"summary": "214 of 4121 against 213 of 3070; risk difference -1.7 points, 95% interval -2.9 to -0.6; NCT02427737, Comfort Talk and Economic Outcomes in MRI",
"record": "/library/comparisons/NCT02427737-68734ccf",
"nct_id": "NCT02427737",
"kind": "outcome",
"participants": 7191,
"risk_difference": {
"value": -0.01745196408006342,
"lower": -0.028919001914788224,
"upper": -0.006341368340036936
},
"group_1": "214 of 4,121",
"group_2": "213 of 3,070",
"difference": "-1.7 points",
"interval": "-2.9 to -0.6",
"trial_title": "Comfort Talk and Economic Outcomes in MRI"
},
{
"id": "NCT01887912-05d1270c",
"title": "C. Difficile Vaccine Group vs Placebo Group: Number of Participants With Symptomatic PCR Confirmed CDI Cases: Per-Protocol Population",
"summary": "23 of 4786 against 13 of 2378; risk difference -0.1 points, 95% interval -0.5 to 0.3; NCT01887912, Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection",
"record": "/library/comparisons/NCT01887912-05d1270c",
"nct_id": "NCT01887912",
"kind": "outcome",
"participants": 7164,
"risk_difference": {
"value": -0.0006610955629276164,
"lower": -0.004844009764276088,
"upper": 0.0026385042778453703
},
"group_1": "23 of 4,786",
"group_2": "13 of 2,378",
"difference": "-0.1 points",
"interval": "-0.5 to 0.3",
"trial_title": "Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=66",
"request_id": "WbCsG5F12xJmdMUn"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant